HealthQuill Pharma
A clutch of 41 multilateral development banks, funders, countries and philanthropies announced a global funding plan to cut greenhouse gas emissions and to protect people from climate risks to health.
Climate Health Pharma

COP28: Funding pathway to cut emissions, protect people from risks

HQ Team November 2, 2023: A clutch of 41 multilateral development banks, funders, countries and philanthropies announced a global funding plan to cut.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
The US Food and Drug Administration (USFDA) is assessing the potential for failures in plastic syringes manufactured in China.
Drugs Health Pharma

FDA probes failure of syringes made in China for possible breakages

HQ Team December 1, 2023: The US Food and Drug Administration (USFDA) is assessing the potential for failures in plastic syringes manufactured in.

Read More
The full year 2023 is set to be the warmest on record with global temperatures rising 1.4 degrees Celsius above pre-industrial levels, as the UN chief called on COP28 nations to set “clear expectations” for climate goals and invest in their implementation. Image Credit: UN
Climate Health Pharma

Record global heat ‘sending shivers down the spines of world leaders’: UN

HQ Team December 1, 2023: The full year 2023 is set to be the warmest on record with global temperatures rising 1.4 degrees.

Read More
Mosquitoes by the evening. Image Credit: Wolfgang Hasselmann on Unsplash
Climate Drugs Pharma

WHO global malaria strategy ‘off track by a wide margin’

HQ Team November 30, 2023: The Covid-19 pandemic significantly disrupted malaria services, leading to a surge in both incidence and mortality rates, exacerbating.

Read More
AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to acquire ImmunoGen, Inc., for $10.1 billion. Image Credit: AbbVie
Drugs Health Pharma

AbbVie to buy Immunogen for $10.1b to expand solid tumour market

HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to.

Read More
The COP28 has reached an agreement to operationalise a fund, known as ‘loss and damage’ to aid developing nations to mitigate the adverse effects of climate change.
Climate Health Pharma

‘Loss and damage’ climate mitigation fund gets going at COP28

HQ Team November 30, 2023: The COP28 has reached an agreement to operationalise a fund, known as ‘loss and damage’ to aid developing.

Read More
The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023 was received with surprise by many. Compared to cereals like rice and wheat, millets were not given much significance and now they are considered as super food with high nutritive value.
Drugs Health Pharma

Opinion: Feast for G20 leaders, benefits of millets exceed rice, wheat

By Dr. K. Leelamoni November 30, 2023: The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023.

Read More
The first human case of a new swine flu variant in the UK has been detected by the Health Security Agency during a polymerase chain reaction testing after the individual had respiratory illness.
Drugs Health Pharma

First new strain of swine flu detected in UK, probe on to track virus origins

HQ Team November 29, 2023: The first human case of a new swine flu variant in the UK has been detected by the.

Read More
The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global health agency reported an 8.9% rise in global prevalence in cases arising in the UK, France and Sweden.
Drugs Health Pharma

Omicron mutant BA.2.86 reclassified as ‘variant of interest’ by WHO 

HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.

Read More